GlobeNewswire Inc.··NaRelmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program
Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial